Search our Database of Scientific Publications and Authors

I’m looking for a

    8403 results match your criteria Psoriatic Arthritis

    1 OF 169

    Psoriatic arthritis: new evidence for old concepts.
    Curr Opin Rheumatol 2017 Oct 13. Epub 2017 Oct 13.
    Rheumatology Unit, Internal Medical Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
    Purpose Of Review: The review gives an updated overview of some of the new concepts in the management of psoriatic arthritis (PsA): early diagnosis, remission as an objective, treat-to-target, and treatment guidelines.

    Recent Findings: Early diagnosis, targeting remission as part of a treatment strategy, and new guidelines providing evidence-based support to these concepts are main topics in recent publications.

    Summary: Dermatologists and rheumatologists should work together to reduce the number of patients remaining undiagnosed, and the time to do so. Read More

    Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
    Case Rep Dermatol 2017 May-Aug;9(2):141-145. Epub 2017 Aug 23.
    Derma-Care Skin and Cosmetology Centre, Mangalore, India.
    Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. Read More

    Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
    Ann Rheum Dis 2017 Oct 13. Epub 2017 Oct 13.
    Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
    Objectives: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases. This study evaluated placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants.

    Methods: CRIB was a pharmacokinetic (PK) study of women ≥30 weeks pregnant receiving commercial CZP for a locally approved indication (last dose ≤35 days prior to delivery). Read More

    A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.
    Rheumatol Ther 2017 Oct 11. Epub 2017 Oct 11.
    Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
    Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab. Read More

    Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.
    Arthritis Res Ther 2017 Oct 10;19(1):226. Epub 2017 Oct 10.
    Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    Background: With expanding therapeutic possibilities for treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to adjust treatment. The rationale behind treatment decisions in current daily clinical practice and the relationship with residual disease activity has not been investigated. The aim of this study was to assess current clinical practice on defining residual disease and subsequent treatment decisions made in PsA patients. Read More

    Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Health Technol Assess 2017 Oct;21(56):1-326
    Centre for Health Economics, University of York, York, UK.
    Background: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA(®), Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Read More

    Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
    Rheumatol Int 2017 Oct 3. Epub 2017 Oct 3.
    Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
    The objective of this study was to describe treatment persistence with second-line subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFis) in patients with immune-mediated rheumatic diseases (IMRDs) in Sweden, and the impact of non-persistence on healthcare costs. This retrospective observational study was based on Swedish national health register data. Adults were identified through filled prescriptions for adalimumab (ADA), etanercept (ETA), certolizumab pegol (CZP) and golimumab (GLM). Read More

    Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.
    World J Gastroenterol 2017 Sep;23(33):6137-6146
    Department of Medical Gastroenterology S, Odense University Hospital, 5000 Odense, Denmark.
    Aim: To investigate whether immune mediated diseases (IMD) are more frequent in patients with inflammatory bowel disease (IBD).

    Methods: In this population based registry study, a total of 47325 patients with IBD were alive and registered in the Danish National Patient Registry on December 16, 2013. Controls were randomly selected from the Danish Civil Registration System (CRS) and matched for sex, age, and municipality. Read More

    Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort.
    Rheumatology (Oxford) 2017 Aug 25. Epub 2017 Aug 25.
    Department of Rheumatology, Royal National Hospital for Rheumatic Diseases.
    Objectives: To describe the time interval between the onset of psoriasis and PsA in the UK primary care setting and compare with a large, well-classified secondary care cohort.

    Methods: Patients with PsA and/or psoriasis were identified in the UK Clinical Practice Research Datalink (CPRD). The secondary care cohort comprised patients from the Bath PsA longitudinal observational cohort study. Read More

    Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    Rheumatology (Oxford) 2017 Aug 16. Epub 2017 Aug 16.
    Novartis Pharma, Basel, Switzerland.
    Objectives: To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA.

    Methods: Patients with PsA ( n = 397) were randomized to s.c. Read More

    Tofacitinib in psoriatic arthritis.
    Immunotherapy 2017 Oct 2. Epub 2017 Oct 2.
    Department of Dermatology, National Taiwan University Hospital & National Taiwan University College of Medicine, Taipei, Taiwan.
    Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents. Tofacitinib is a Janus family of kinases inhibitor approved for treating rheumatoid arthritis in many countries and psoriasis in Russia. Read More

    Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
    J Rheumatol 2017 Oct 1. Epub 2017 Oct 1.
    From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. Sponsored by Corrona LLC. Corrona LLC has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, BMS, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB. LRH is an employee and shareholder of Corrona LLC, and has a research grant to the University of Massachusetts Medical School from Pfizer. BSS, DHC, and AM are employees and shareholders of Amgen Inc. SR and WM are employees of Corrona LLC. SWW is a consultant of Amgen Inc. JDG is an employee and shareholder of Corrona LLC, and a consultant of Eli Lilly, Genentech, Janssen, Novartis, and Pfizer. CJE is an employee of Corrona LLC and an advisory board member for Merck. L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center. Address correspondence to Dr. L.R. Harrold, University of Massachusetts Medical School, Medicine, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Accepted for publication July 19, 2017.
    Objective: Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA).

    Methods: Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation.

    Results: Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8. Read More

    Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.
    Clin Exp Med 2017 Sep 30. Epub 2017 Sep 30.
    Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Insurgentes 244-1, Lomas de Atemajac, 45178, Zapopan, Guadalajara, Jalisco, Mexico.
    Psoriatic arthritis (PsA) is an autoimmune inflammatory disease associated with psoriasis. The cause of this pathology is still unknown, but research suggests the diseases are caused by a deregulated cytokine production. MIF is a cytokine associated with immunomodulation of Th1, Th2, and Th17 cytokine profiles in inflammatory diseases. Read More

    Damage-associated molecular patterns and their role as initiators of inflammatory and auto-immune signals in systemic lupus erythematosus.
    Int Rev Immunol 2017 Sep 29:1-12. Epub 2017 Sep 29.
    a Grupo de Inmunología Celular e Inmunogenética , Universidad de Antioquia , carrera 53 numero 61-30, Medellin , Colombia.
    Damage-associated molecular patterns (DAMPs) are endogenous molecules that are released into the extracellular space under conditions of activation, cellular stress, or tissue damage. These molecules are recognized by pattern-recognition receptors (PRRs) and can induce inflammation and immune responses in the absence of infection. An increasing number of DAMPs have been linked to the pathogenesis of many auto-immune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis, and systemic sclerosis (SSc); as they promote the maturation/activation of different immune cells and pro-inflammatory cytokines production associated with these diseases. Read More

    Anti-IL-23 and anti-IL-17 biologic agents for the treatment of immune-mediated inflammatory conditions.
    Clin Pharmacol Ther 2017 Sep 28. Epub 2017 Sep 28.
    Baylor Scott and White- Division of Dermatology, 3900 Junius Street, Ste 145, Dallas, TX 75246.
    Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)-23 and IL-17 as fundamental contributors in the immune pathways of the disease. Leveraging these promising therapeutic targets has led to the emergence of a number of anti-IL-23 and -17 biologic agents with the potential to treat multiple conditions with common underlying pathology. The unprecedented clinical efficacy of these agents in the treatment of psoriasis has paved way for their evaluation in diseases such as psoriatic arthritis, Crohn's disease, rheumatoid arthritis, in addition to other immune-mediated conditions. Read More

    Associations between coronary and carotid artery atherosclerosis in patients with inflammatory joint diseases.
    RMD Open 2017 17;3(2):e000544. Epub 2017 Sep 17.
    Department of Radiology, Oslo University Hospital, Oslo, Norway.
    Objective: Low association between cardiac symptoms and coronary artery disease (CAD) in patients with inflammatory joint diseases (IJD) demands for objective markers to improve cardiovascular risk stratification. Our main aim was to evaluate the prevalence and characteristics of CAD in patients with IJD with carotid artery plaques. Furthermore, we aimed to assess associations of carotid ultrasonographic findings and coronary plaques. Read More

    Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3.
    RMD Open 2017 13;3(1):e000413. Epub 2017 Jul 13.
    Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.
    Background: The risk of osteoporosis in patients with psoriatic arthritis (PsA) remains unclear. The aim of this study was to compare bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) in patients with PsA and controls.

    Patients And Methods: Patients with PsA and controls were recruited from the Nord-Trøndelag Health Study (HUNT) 3. Read More

    Comparison of 25-hidroksi Vitamin D serum concentrations in patients with psoriasis and psoriatic arthritis.
    J Back Musculoskelet Rehabil 2017 Sep 8. Epub 2017 Sep 8.
    Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Sakarya University Medical Faculty, Sakarya, Turkey.
    Background And Object: Rheumatoid arthritis (RA), insulin-dependent diabetes mellitus (IDDM), inflammatory bowel disease, systemic lupus erythematosus (SLE) and multiple sclerosis (MS) are some of the autoimmune diseases related to the decreases in Vitamin D levels. The same immunological properties as psoriasis, such as Th1/Th2 dysregulation, are seen in all of them. This study aims to compare 25-hidroksi Vitamin D (25-OHD) serum concentrations in patients with psoriasis and psoriatic arthritis. Read More

    Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    J Med Econ 2017 Sep 25:1-21. Epub 2017 Sep 25.
    h Toronto Western Hospital, University of Toronto , Toronto , Ontario , Canada.
    Objective: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, versus currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective.

    Methods: A decision analytic semi-Markov model evaluated the cost-effectiveness of secukinumab 150mg and 300mg compared to subcutaneous biologics adalimumab, certolizumab pegol, etanercept, golimumab, and ustekinumab and intravenous biologics infliximab and infliximab biosimilar in biologic-naive and biologic-experienced patients over a lifetime horizon. The response to treatments was evaluated after 12 weeks by PsA Response Criteria (PsARC) response rates. Read More

    The reliability and validity of a Venezuelan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
    Reumatol Clin 2017 Sep 21. Epub 2017 Sep 21.
    School of Allied Health Sciences. Searly Center Aging, Galveston, Texas, EE. UU.
    Introduction: Spondyloarthropathies (SpA) are disabling diseases with a prevalence of 1.9% in the general population. The indices designed for monitoring the disease should be valid, reliable and cross-culturally adapted for decision-making concerning the appropriate treatment. Read More

    GP2015: An Etanercept Biosimilar.
    BioDrugs 2017 Sep 23. Epub 2017 Sep 23.
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. GP2015 has similar physiochemical and pharmacodynamic properties to those of reference etanercept, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers. Read More

    Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study.
    Arthritis Res Ther 2017 Sep 21;19(1):210. Epub 2017 Sep 21.
    Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK.
    Background: A recent systematic review identified four candidate serum-soluble bone-turnover biomarkers (dickkopf-1, Dkk-1; macrophage-colony stimulating factor, M-CSF; matrix metalloproteinase-3, MMP-3; osteoprotegerin, OPG) showing possible association with psoriatic arthritis (PsA). We aimed to: (i) confirm and determine if these four biomarkers are associated with PsA; (ii) differentiate psoriasis cases with and without arthritis; and (iii) differentiate PsA cases with and without axial arthritis.

    Methods: A prospective cross-sectional comparative two-centre study recruited 200 patients with psoriasis without arthritis (PsC), 127 with PsA without axial arthritis (pPsA), 117 with PsA with axial arthritis (psoriatic spondyloarthritis, PsSpA), 157 with ankylosing spondylitis (AS) without psoriasis, and 50 matched healthy controls (HC). Read More

    Effects of secukinumab on serum adipocytokines: preliminary data.
    Reumatismo 2017 Sep 21;69(3):105-110. Epub 2017 Sep 21.
    Unit of Rheumatology, University of Verona.
    Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, connective tissues and the axial skeleton. Metabolic syndrome is an independent risk factor for psoriasis (Pso) development and is associated with more severe forms of Pso. Adipocytokines are secreted by white adipose tissue and are thought to link obesity with the development of metabolic and cardiovascular diseases. Read More

    Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis.
    Open Access Maced J Med Sci 2017 Aug 11;5(5):651-656. Epub 2017 Aug 11.
    Internal Medicine Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
    Background: To our knowledge, the correlation between ultrasonographic enthesopathy and severity in psoriatic arthritis (PsA) has been done before. However, the correlation between ultrasonography of enthesopathy and the Psoriatic Arthritis Disease Activity Score (PASDAS) have not been done.

    Aim: To compare the results of ultrasonographic enthesopathy of foot and PASDAS in PsA. Read More

    Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study.
    Front Pharmacol 2017 6;8:607. Epub 2017 Sep 6.
    The authors would like to thank all the members of the BIO-Cam group who provided patient data for this study: University Hospital of Università degli Studi della Campania "Luigi Vanvitelli" Naples; Hospital SG Moscati-Avellino; Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale" Naples; Hospital AORN Cardarelli Naples; Hospital G Rummo Benevento; Hospital Sant'Anna e San Sebastiano Caserta; University Hospital Università degli Studi di Napoli Federico II Naples; Fondazione Maugeri Benevento; University Hospital San Giovanni di Dio e Ruggi d'Aragona Salerno; Hospital Ospedale dei Colli Naples.
    Objectives: To investigate the occurrence of adverse events (AEs) in naïve patients receiving biotech drugs. Design: A prospective observational study. Setting: Onco-hematology, Hepato-gastroenterology, Rheumatology, Dermatology, and Neurology Units in Campania Region (Italy). Read More

    A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis.
    J Clin Rheumatol 2017 Sep 19. Epub 2017 Sep 19.
    From the Departments of *Internal Medicine and †General Internal Medicine, University of Arizona, Tucson, AZ; ‡Bronx-Lebanon Hospital Center, Mount Sinai School of Medicine, Bronx, NY; §Rheumatology Care Specialists, Franciscan Physician Network, Indianapolis, IN; ∥Division of Rheumatology, Department of Internal Medicine, University of Arizona, Tucson, AZ; and ¶Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH.
    Objective: The aim of this study was to systemically review the efficacy and safety of inhibitors of interleukin 6 (IL-6): clazakizumab, IL-12/23: ustekinumab, and IL-17A: secukinumab, brodalumab, and ixekizumab in psoriatic arthritis (PsA).

    Methods: The literature search was conducted using MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science. We included randomized controlled trials that assessed the efficacy of IL inhibitors and reported American College of Rheumatology 20 response at 24 weeks. Read More

    The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis.
    Curr Rheumatol Rep 2017 Sep 18;19(10):66. Epub 2017 Sep 18.
    Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
    Purpose Of Review: In this review, we synthesize current data on non-adherence across inflammatory arthritides and explore (1) the effects of economic factors on non-adherence and (2) the impacts of non-adherence on economic outcomes.

    Recent Findings: Recent evidence demonstrates medication non-adherence rates as high as 74% in ankylosing spondylitis (AS), 90% in gout, 50% in psoriatic arthritis (PsA), 75% in systemic lupus erythematosus (SLE), and 82% in rheumatoid arthritis (RA). The effects of socioeconomic factors have been studied most in RA and SLE but with inconsistent findings. Read More

    New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.
    Drug Des Devel Ther 2017 30;11:2527-2535. Epub 2017 Aug 30.
    Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy.
    Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population. The prevalence of nail involvement in psoriasis patients varies between 15% and 79%. While the nails represent a small portion of the body surface area, psoriasis in these areas can have a disproportionate influence on a patient's physical and psychosocial activities. Read More contribution to the knowledge of immune-mediated systemic rheumatic diseases.
    Acta Reumatol Port 2017 Jul-Sep;42(3):232-239
    Centro Hospitalar Baixo Vouga.
    Patient registries are key instruments aimed at a better understanding of the natural history of diseases, at assessing the effectiveness of therapeutic interventions, as well as identifying rare events or outcomes that are not captured in clinical trials. However, the potential of registries goes far beyond these aspects. For example, registries promote the standardization of clinical practice, can also provide information on domains that are not routinely collected in clinical practice and can support decision-making. Read More

    The spectrum of psoriatic arthritis in a South African cohort.
    Clin Rheumatol 2017 Nov 15;36(11):2501-2507. Epub 2017 Sep 15.
    Department of Medicine, Division of Rheumatology, University of Cape Town, Cape Town, South Africa.
    The aim of this study was to describe the clinical features of patients with psoriatic arthritis (PsA) in a South African cohort. This is a retrospective analysis of patients contributing to development of the international classification criteria for PsA, ClASsification criteria for Psoriatic ARthritis (CASPAR). Patients were all seen at the arthritis clinics at Groote Schuur Hospital, Cape Town. Read More

    [Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].
    Gan To Kagaku Ryoho 2017 Sep;44(9):787-789
    Dept. of Thoracic Surgery, National Hospital Organization, Kanagawa National Hospital.
    Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-relatedad verse events.

    Case Presentation: A 66-year-oldman without any history of autoimmune disease was referredto our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage III A non-small-cell lung cancer by using bronchoscopic biopsy, computedtomography, andFDG -PET. Read More

    Fever as an initial manifestation of spondyloarthritis: A retrospective study.
    PLoS One 2017 14;12(9):e0184323. Epub 2017 Sep 14.
    Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
    Objectives: We aimed to evaluate a wide spectrum of clinical features of adult patients with spondyloarthritis (SpA) whose initial manifestation was fever, using the Assessment of SpondyloArthritis international Society (ASAS) classification criteria.

    Methods: We retrospectively collected the electronic medical records of hospitalized SpA patients who initially presented to the Severance Hospital (Seoul, Korea) with fever from January 2010 to May 2016. As a control group, we also recruited one-hundred consecutive patients who were diagnosed with SpA in our outpatient clinic. Read More

    The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.
    Bull Hosp Jt Dis (2013) 2017 May;75(3):155-163
    Psoriasis is a common autoimmune disorder that affects the skin. Approximately 30% of individuals with psoriasis will develop inflammatory arthritis, often in the setting of human leukocyte antigen B27. Both forms of disease are thought to be the result of prolonged inflammation mediated by T lymphocytes, dendritic cells, and keratinocytes. Read More

    Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    J Eur Acad Dermatol Venereol 2017 Sep 12. Epub 2017 Sep 12.
    Department of Dermatology, Academic Medical Center, University of Amsterdam, the Netherlands.
    Background: Biologics have greatly improved psoriasis management. However, primary and secondary non-response to treatment requires innovative strategies to optimize outcomes.

    Objective: To describe the use of combined treatment of biologics with conventional systemic agents or phototherapy in daily clinical practice. Read More

    Small molecule therapy for managing moderate to severe psoriatic arthritis.
    Expert Opin Pharmacother 2017 Oct 18;18(15):1557-1567. Epub 2017 Sep 18.
    a Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
    Introduction: The majority of psoriatic arthritis (PsA) patients experience a good clinical response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic therapies (bDMARDs). However, treatment failure with these drugs can represent a relevant clinical problem. Moreover, in daily clinical practice, the appropriate identification of patients eligible for these agents can be conditioned by numerous aspects, mainly represented by comorbidities, such as history of malignancies, chronic and recurrent infectious diseases. Read More

    Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.
    Clin Rheumatol 2017 Nov 9;36(11):2487-2495. Epub 2017 Sep 9.
    Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
    Data on the progression of atherosclerosis in spondyloarthritis (SpA) are scarce, despite a high burden of cardiovascular diseases (CVD). The aim of this study was to identify the predictors of an accelerated subclinical atherosclerosis in patients with SpA. Study participants were 66 patients free of CVD classified according to ASAS criteria. Read More

    Psoriasis pathogenesis and the development of novel targeted immune therapies.
    J Allergy Clin Immunol 2017 Sep;140(3):645-653
    Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address:
    Psoriasis is caused by a complex interplay between the immune system, psoriasis-associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease primarily driven by pathogenic T cells that produce high levels of IL-17 in response to IL-23. The discovery of the central role for the IL-23/type 17 T-cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition. Read More

    Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis.
    Rheumatol Int 2017 Sep 6. Epub 2017 Sep 6.
    Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, P.O. Box 188, 221 00, Lund, Sweden.
    The aim was to investigate whether secular trends in sickness absence (SA) were present in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) receiving their diagnosis between 2002 and 2011. A repeated cross-sectional study design was used. Patients were identified in the Skåne Healthcare Register (SHR). Read More

    Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis.
    RMD Open 2017 16;3(2):e000486. Epub 2017 Aug 16.
    Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway.
    Objective: To compare clinical and ultrasonographic (US) evaluation of Achilles enthesitis in patients with psoriatic arthritis (PsA).

    Methods: The Achilles insertion of outpatients with PsA was examined by clinical assessment of tenderness and US evaluation of (1) inflammatory activity (defined as the presence of power Doppler signal, tendon thickening and/or hypoechogenicity) and (2) structural damage (defined as the presence of erosions, calcifications and/or enthesophytes). Univariate and multivariate logistic regression analyses were performed0. Read More

    An Atypical Presentation of Retroperitoneal Fibrosis.
    Curr Urol 2017 Aug 30;10(3):157-159. Epub 2017 Jul 30.
    Department of Urology, Rush University Medical Center, Chicago, Illinois, USA.
    A 69-year-old man with a psoriatic arthritis treated with infliximab for 1 month presented to the urology clinic for lower urinary tract symptoms. He was found to have a new diagnosis of elevated creatinine. Computed tomography of the abdomen and pelvis revealed bilateral severe hydronephrosis with abnormal soft tissue thickening of the right renal pelvis and proximal ureter. Read More

    Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.
    Clin Transl Immunology 2017 Aug 25;6(8):e152. Epub 2017 Aug 25.
    Novartis Pharma AG, Basel, Switzerland.
    Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and in vitro findings examining the effect of secukinumab on Mycobacterium tuberculosis infection. Read More

    Comics as an educational tool for children with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J 2017 Sep 2;15(1):69. Epub 2017 Sep 2.
    Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, 59 Tschernihovsky St, 44281, Kfar Saba, Israel.
    Background: This study examined whether the comic book Neta and the Medikidz Explain JIA would improve disease-related knowledge and treatment adherence among patients with juvenile idiopathic arthritis (JIA).

    Methods: In this prospective cohort study, JIA patients answered 20 multiple-choice knowledge questions about their disease, before and after reading the comic book. Demographic, clinical, health-related quality of life and adherence data were recorded and correlated to the responses. Read More

    Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.
    BMJ Open 2017 Aug 30;7(8):e016619. Epub 2017 Aug 30.
    Janssen Inc., Toronto, Ontario, Canada.
    Objective: To describe the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents, evaluate prognostic factors of MDA achievement and identify the most common unmet criteria among MDA achievers.

    Design: Biologic Treatment Registry Across Canada (BioTRAC): ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis, ankylosing spondylitis or PsA with infliximab (IFX), golimumab (GLM) or ustekinumab.

    Setting: 46 primary-care Canadian rheumatology practices. Read More

    Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.
    Clin Rev Allergy Immunol 2017 Aug 29. Epub 2017 Aug 29.
    Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, University of Cantabria, Avda. de Valdecilla, s/n, 39008, Santander, Spain.
    The term inflammatory joint disease (IJD) encompasses a group of chronic conditions with predominant joint involvement. They share an increased risk of cardiovascular (CV) complications. However, the implication of the sex in the risk of CV disease in IJD has not been specifically addressed. Read More

    Is there any link between tumor-induced osteomalacia and psoriasis? A case report.
    J Diabetes Metab Disord 2017 23;16:34. Epub 2017 Aug 23.
    Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
    Background: Tumor-induced osteomalacia is an uncommon paraneoplastic syndrome caused by Fibroblast growth factor-23-secreting tumors. It is characterized by phosphaturia, hypophosphatemia, and a high plasma level of alkaline phosphatase.

    Case Presentation: We report a young patient with psoriasis who had suffered from bone pain and muscle weakness for more than 6. Read More

    IL-23 and Th17 Disease in Inflammatory Arthritis.
    J Clin Med 2017 Aug 29;6(9). Epub 2017 Aug 29.
    Institute of Rheumatology, Tokyo Women's Medical University 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan.
    IL-23, which is composed of p19 and p40 subunits, is a proinflammatory cytokine that contributes to the formation and maintenance of Th17 cells in inflammatory autoimmune diseases. IL-23 is a human osteoclastogenic cytokine and anti-IL-23 antibody attenuates paw volume and joint destruction in CIA rats. IL-23 levels in serum and synovial fluid are high in rheumatoid arthritis (RA) patients, and IL-23 may be a useful biomarker for the diagnosis of RA. Read More

    1 OF 169